Some news from our southern neighbors (i.e. from Danish Genmab).
1. New appointment.
Dr. Ernst Schweizer Appointed Head of Business Development at Genmab
Copenhagen, Denmark – 21th January 2002
Genmab A/S (CSE: GEN and Neuer Markt: GE9D) today announced that Dr. Ernst Schweizer has been appointed Head of Business Development for the company.
Dr. Schweizer was most recently President of Medarex Europe and was previously the Deputy Director of Worldwide Business Development and Licensing for Novartis and Chief Scientific and Technical Adviser of Business Development and Licensing at Ciba-Geigy. He is a member of the Board of Directors at CoMab, Hyseq, Speedel and BioPharma Fund. Dr. Schweizer received his Ph.D. from the University of Stuttgart.
“Dr. Ernst Schweizer brings a wealth of industry experience and knowledge to Genmab and will be a valuable member of the senior management team,” said Genmab’s CEO Dr. Lisa N. Drakeman. “We look forward to him leading the business development team through what is for Genmab an exciting time of growth.”
Dr. Schweizer takes up his post immediately.
Why they are shifting staff from Medarex to Genmab is beyond me. Should we see this as a sign that Medarex are giving up on the European market and shifting these responsibilities to Genmab? Or was his sojourn at Medarex just a part of his introductory ideological education?
No, I don't think so (after checking Medarex's news archive). He arrived in the US already 1999.
ANNANDALE, N.J., May 6 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX), a leading biopharmaceutical company, today announced the appointment of Dr. Ernst Schweizer as President of Medarex Europe.
Prior to Medarex, Dr. Schweizer served as the Deputy Head of Business Development and Licensing at Novartis, where he was responsible for numerous strategic licensing agreements for products exceeding $1 billion in annual sales. Previously, he was the chief scientific and technical adviser in business development and licensing at CIBA-Geigy. During his 36 years with Novartis and CIBA-Geigy, Dr. Schweizer has earned an international reputation as a thought leader in pharmaceutical drug discovery and development. Dr. Schweizer, who also served as a group leader in pharmaceutical research at CIBA-Geigy, has a Ph.D. from the University of Stuttgart and holds numerous patents.
Whatever the reason - they seem to be planning for a lot of business in Copenhagen.
2. Research and Development Day
A re-broadcast from Genmab's R&D day is "in principle" available at the following URL:
investormedia.de
The "in principle" stems from the fact that a successful reception seems to be depending on the combination of Web-browser and Media Player one is using. In my case it only runs on the machine I have no audio on. I don't think that was their intention. Another example of MS screwing up the free exchange of information over the internet, I suppose.
Ice |
